MedTrace Logo

Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer

NCT04113096 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2019-10-08

No results posted yet for this study

Summary

This study is being done to find the effect of Dibenzyl Trisulphide (active ingredient in Guinea Hen Weed in combination in patients with stage four cancer of the breast, prostate, cervix and colon.

Conditions

  • Stage IV Prostate Cancer
  • Stage IV Colon Cancer
  • Stage IV Breast Cancer
  • Stage IV Cancer of the Cervix

Interventions

DRUG

Dibenzyl trisulphide capsules

20 mg once daily for 6 months

DRUG

Dibenzyl trisulphide capsules

20 mg once daily for 6 months

DRUG

Dibenzyl trisulphide capsules

20 mg once daily for 6 months

DRUG

Dibenzyl trisulphide capsules

20 mg once daily for 6 months

DRUG

Stage IV Breast Cancer Placebo

20 mg once daily for 6 months

DRUG

Stage IV: Colon Cancer Placebo

20 mg once daily for 6 months

DRUG

Cervical Cancer Stage IV Placebo

20 mg once daily for 6 months

DRUG

Cancer of the Prostate Placebo

20 mg once daily for 6 months

Sponsors & Collaborators

  • The University of The West Indies

    lead OTHER

Principal Investigators

  • LAD Williams · University of the West Indies, Mona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Jamaica

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04113096 on ClinicalTrials.gov